Underlying the FARG signature, it was first identified in the present study that among all FGFR3 alterations, c.746C>G (p.Ser249Cys) was significantly more prevalent in the low-risk group; however, it was found in the present study that this mutation site was not significantly correlated with OS of BC patients, whereas there were few studies currently focusing on the FGFR3 mutation site c.746C>G (p.Ser249Cys), except that FGFR antagonists could inhibit TCC97-7-type BC cells that carried the c.746C>G (p.Ser249Cys) of FGFR3 mutation (40). The gene discussed is FGFR3; the disease is breast cancer.